3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Enrique Gomez of Texas Medical Center Innovation, Katie Eick of Rockin' Pets Rollin' Vets, and Jim Gable of Chevron. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from health care innovation to energy — recently making headlines in Houston innovation.

Enrique Gomez, entrepreneur in residence at Texas Medical Center Innovation

Enrique Gomez joins the Houston Innovators Podcast to discuss Houston as an oncology innovation hub. Photo via TMC.edu

When it comes to leading oncology innovation, Houston has a seat at the table, Enrique Gomez, entrepreneur in residence at Texas Medical Center Innovation's Accelerator for Cancer Therapeutics, says on the Houston Innovators Podcast.

"Houston is a place where everyone looks at when it comes to novel research and approaches to treating cancer," Gomez says. "The landscape here is going to be accelerated because we see much more collaboration between the founding institutions — and that's a very important element of growth. Houston has no comparison to any other place in terms of what's going on here and the level and quality of research."Click here to read more and stream the episode.

Katie Eick, founder of Rollin' Vets

Katie Eick always wanted to be able to offer mobile services. Photo courtesy of Rollin' Vets

Houston-based Rockin' Pets, Rollin' Vets, a full-service mobile veterinary clinic based in Houston, has closed a $5 million equity raise with plans to expand across the Lone Star State. Founded by Dr. Katie Eick, who is the company's CEO, Rollin’ Vets Group flips the switch on pet health care by bringing vets to its patients' homes.

This fresh funding helps Eick take that first step toward expansion. According to a news release, Rockin’ Pets, Rollin’ Vets expects to have a presence in Dallas and Austin by March of next year.

“This equity raise allows us to not only hire additional talent, but also increase our mobile clinic fleet, while expanding into other cities at an expedited rate. There is a vast opportunity to serve animals and people that need non-traditional veterinary care in other Texas markets. We are ready to tap into these markets and bring convenient, state-of-the-art care straight to pet owners’ doorsteps,” says Eick in the release. Click here to read more.

Jim Gable, incoming vice president of innovation and president of Chevron Technology Ventures

Barbara Burger has led Chevron's innovation efforts for almost a decade and is passing the responsibilities to Jim Gable. Photo courtesy

Barbara Burger, vice president of innovation at Chevron and president of Chevron Technology Ventures, is retiring, and passing the role to Jim Gable.

Gable brings his 23 years of experience to the role. Based in Chevron's office on the West Coast, he will be relocating to Houston, per the release. He currently oversees the development and deployment of downstream-related technology for Chevron.

“CTV has a 22-year history of investing in startups across a wide cross section of energy innovation and a track record of collaboration to bring innovation to scale,” Bonner continues. “Jim’s experience at Chevron is deep and diverse. Combined with his technology commercialization experience with CTV early in his career, as well as in his current role, Jim is poised to lead CTV to even greater success.” Click here to read more.

Enrique Gomez joins the Houston Innovators Podcast to discuss Houston as an oncology innovation hub. Photo via TMC.edu

How Houston is emerging as a leader for oncology innovation, according to this expert

Houston innovators podcast episode 114

Houston is currently establishing itself as a hub for health care innovation — and Enrique Gomez should know. He's worked in the field of biopharmaceuticals across the continent.

As entrepreneur in residence at Texas Medical Center Innovation's Accelerator for Cancer Therapeutics, he works with early stage startups and researchers. However, for decades he's worked in a much later stage of drug development, holding leadership positions at Takada in Latin America and Shire in Boston.

"Texas is very well recognized for cancer therapeutics," Gomez says on this week's episode of the Houston Innovators Podcast. "There's a lot of research going on. These researchers are looking at every angle — every possible strategy to tackle cancer."

At ACT, Gomez connects the startups or instigators with the resources they need to get their life-saving solutions to market. With cancer, there's not one thing that's going to work. There have to be options for treating cancer.

"Cancer is very heterogeneous. Not one strategy will be the single silver bullet to overcome the disease," Gomez says. "We are talking about personalized medicine. Every person is different and every cancer in every patient is different. It will require a number of approaches to overcome the health situation."

Thankfully, through TMC's ACT and the numerous research institutions working on the future of oncology, Houston's a great spot to move that needle.

"Houston is a place where everyone looks at when it comes to novel research and approaches to treating cancer," Gomez says. "The landscape here is going to be accelerated because we see much more collaboration between the founding institutions — and that's a very important element of growth. Houston has no comparison to any other place in terms of what's going on here and the level and quality of research."

He shares more on how COVID-19 has affected drug development and research — as well as what's next for his own career — on the podcast. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Top stories: Houston's most-read health tech news of 2024

year in review

Editor's note: As the year comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. In the health tech category on InnovationMap, top stories included startup funding raised, IPO plans, FDA clearance, and more. Be sure to click through to read the full story.

New report ranks Houston top market for life sciences

Houston lands in the No. 7 spot for growth in the granting of degrees in biological and biomedical sciences. Photo by Natalie Harms/InnovationMap

Thanks in large part to producing hundreds of college-trained professionals, Houston’s life sciences industry ranks among the top U.S. markets for talent in 2024.

In a report published by commercial real estate services company CBRE, Houston lands in the No. 7 spot for growth in the granting of degrees in biological and biomedical sciences. From 2017 to 2022, Houston notched a growth rate of 32.4 percent in this category.

In 2022, the University of Houston led the higher education pack in the region, graduating 746 people with a bachelor’s degree or above in biological or biomedical sciences, according to the report. Continue reading.

Houston innovator raises pre-seed funding for health care staffing platform

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. Photo courtesy of Lokum

A Houston health care innovator is celebrating an oversubscribed round of pre-seed funding to improve on her startup's unique staffing platform.

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. The new platform, which cuts out the middleman and lowers staffing costs, raised $700,000 in pre-seed funding that will go toward further development of the technology.

"Healthcare organizations spend $26 billion annually to support a crippling dependence on third-party agencies for connecting with clinical staff," Ademuyewo says in a news release. "Technological solutions that are pointed precisely to streamline and strengthen the relationships between highly specialized clinicians and their future employers are vital to alleviating this detrimental dependance, and central to our mission." Continue reading.

Houston regenerative medicine company to IPO, move toward more human trials

FibroBiologics will IPO this week. Photo via Getty Images

Want a piece of one of Houston’s most promising biotech companies? On January 31, FibroBiologics will begin the trading of its common stock on the Nasdaq stock exchange.

While most labs in the realm of regenerative medicine are focused on stem cells, FibroBiologics has bet on fibroblasts as the secret to treating myriad ailments. Fibroblasts, the most common type of cell in the body, are the primary cells that compose connective tissue.

Interested investors can find a prospectus to peruse before taking the leap. FibroBiologics filed with the U.S. Securities & Exchange Commission (SEC) on November 7, 2023. In September, FibroBiologics CEO Pete O’Heeron told InnovationMap, “I think what we're going to see is that fibroblasts are going to end up winning... They're just a better overall cell than the stem cells.” Continue reading.

Houston organizations identify promising life science cos. at annual event

The Rice Alliance and BioHouston acknowledged innovations from a dozen promising health tech companies. Photo via Rice University

For the 13th year, the Texas Life Science Forum hosted by BioHouston and the Rice Alliance for Technology and Entrepreneurship celebrated innovative companies from around the world that are creating new treatments and solutions to today's biggest health care challenges.

This week, over 40 companies presenting their innovations across cancer, cardiovascular disease, biotechnology, and more. Nearly 700 venture capitalists, corporate innovation groups, angel networks, industry leaders, academics, service providers, and others attended the event on November 7 at Rice's BioScience Research Collaborative in the Texas Medical Center.

Just like in previous years, the event ended with the announcement of the 10 companies that were deemed "most promising" based on their pitches and technologies. Of the 10 companies named, six are headquartered in Houston and an additional two startups on the list have a presence here. Continue reading.

FDA greenlights Houston surgery robotics company's unique technology

EndoQuest Robotics secured an Investigational Device Exemption from the FDA for its clinical study. Photo via Getty Images

A Houston surgical robotics company has gotten a Investigational Device Exemption from the FDA to go forward with human trials.

This news allows EndoQuest Robotics to begin its Prospective Assessment of a Robotic-Assisted Device in Gastrointestinal Medicine (PARADIGM) study, which will be conducted at leading United States health care facilities, including Brigham and Women’s Hospital (Boston), Mayo Clinic (Scottsdale), Cleveland Clinic (Cleveland), AdventHealth (Orlando), and HCA Healthcare (Houston). The study will include surgeries on 50 subjects, who will hopefully begin to enroll in January.

“The foundational thesis is we're trying to make sure that the world's largest medical center is also the world's largest med tech innovation center,” Eduardo Fonseca, interim CEO of EndoQuest Robotics, tells InnovationMap. Continue reading.

Houston biotech biz to merge with public co., set local HQ

big deal

Houston-based Tvardi Therapeutics and Cara Therapeutics announced the companies have entered into a definitive merger agreement to combine in an all-stock transaction. Once completed, Houston will house the headquarters.

Tvardi is a clinical-stage biopharmaceutical company that focuses on the development of novel, oral, and small molecule therapies that target STAT3 to treat fibrosis-driven diseases. Tvardi will merge with a wholly owned subsidiary of Cara.

Once complete, the pre-merger Cara Therapeutics stockholders are expected to own approximately 17 percent of the combined company and pre-merger Tvardi Therapeutics investors are expected to own 83 percent of the combined company. Prior to adjustment from the issuance of the shares in the recently completed Tvardi financing and assuming Cara, which went public in 2014, has net cash at closing of between $22.9 million and $23.1 million with the percentage of the combined company that pre-merger Cara stockholders and pre-merger Tvardi stockholders will own upon the closing of the merger, which is subject to further adjustment if Cara’s net cash balance falls outside of the range.

“As we approach meaningful value inflection points next year, including two Phase 2 readouts of our lead program in idiopathic pulmonary fibrosis, followed by the readout in our hepatocellular carcinoma program, this merger, the recently completed financing, and becoming a publicly traded company give us access to the critical funding required to further advance our promising pipeline programs that address significant unmet needs,” Imran Alibhai, CEO of Tvardi Therapeutics, says in a news release.

Also, Tvardi has completed an approximately $28 million private financing from a syndicate of new and existing institutional investors. With the cash from both companies at closing and the proceeds of this financing, the post-merger company plans to have cash to fund its operating expenses and capital expenditure requirements into the second half of 2026.

“I am grateful to the Cara Board, leadership team, and shareholders who share our vision of Tvardi that is well-positioned to introduce effective, new treatment options to patients suffering from serious, chronic, fibrosis-driven diseases,” Alibhai continues.

In 2021, Tvardi emerged from stealth and closed a $74 million series B funding round led by New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

Looking back: Top 5 most-read Houston space tech articles of 2024

year in review

Editor's note: As 2024 comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. In the Space City, there were dozens of space tech stories, from experts' thoughts on commercialization to the IPO of a Houston company. Here are five Houston space tech-focused articles that stood out to readers this year — be sure to click through to read the full story.

Houston space tech co. rolls out futuristic lunar rover for NASA's Artemis missions

Intuitive Machine unveiled its RACER lunar terrain vehicle at Space Center Houston. Photo courtesy of Intuitive Machines

Houston-based space exploration company Intuitive Machines just unveiled its version of a lunar terrain vehicle that’s designed to be used by astronauts in NASA’s Artemis moon discovery program.

Intuitive Machine recently rolled out its RACER lunar terrain vehicle (LTV) at Space Center Houston. RACER stands for Reusable Autonomous Crewed Exploration Rover.

The rover can accommodate two astronauts and nearly 900 pounds of cargo. In addition, it can pull a trailer loaded with almost 1,800 pounds of cargo. Continue reading.

Axiom Space CEO steps down, search begins for replacement

Axiom Space Co-founder Michael Suffredini is stepping down as CEO. Photo courtesy of Axiom Space

Houston-based space exploration company Axiom Space is searching for a new CEO.

Co-founder Mike Suffredini stepped down effective August 9 as CEO. He cites unidentified personal reasons for his transition from CEO to company advisor. Suffredini remains a board member of Axiom Space.

Co-founder Kam Ghaffarian, the company’s executive chairman, is serving as interim CEO until Axiom Space taps Suffredini’s permanent successor.

“We are grateful for Mike’s invaluable contributions to human space exploration and the remarkable growth of Axiom Space,” Ghaffarian says in a news release. “He will continue to offer his unique perspective and expertise as we advance our mission.” Continue reading.

Houston space tech company secures $116.9M NASA contract

The $116.9 million agreement will task Intuitive Machines with delivering six science and technology payloads to the moon. Photo courtesy of Intuitive Machines

NASA is again entrusting a Houston space business with lunar deliveries.

Intuitive Machines (Nasdaq: LUNR, LUNRW) has secured its fourth contract with NASA’s Commercial Lunar Payload Services, or CLPS, program. The $116.9 million agreement will task Intuitive Machines with delivering six science and technology payloads, which will include one European Space Agency-led drill suite to the Moon’s South Pole.

“Over the last several years, we’ve witnessed NASA’s successful Artemis I mission and the campaign’s progress toward sustainably returning humans to the surface of the Moon, highlighting the importance of autonomous missions that advance humanity’s understanding of the Moon and the commercial services required to support the industry,” Intuitive Machines CEO Steve Altemus says in a news release. “Intuitive Machines looks forward to working closely with the NASA team to deliver mission success once again.” Continue reading.

Houston Spaceport takes off with second phase of development

The next phase of the Houston Spaceport will build out connectivity and workforce training. Rendering via Houston Airports

Since the Houston Spaceport secured the 10th FAA-Licensed commercial spaceport designation in 2015, the development's tenants have gone on to secure billions in NASA contracts. Now, the Houston Spaceport is on to its next phase of growth.

“Reflecting on its meteoric rise, the Spaceport has seen remarkable growth in a short span of time. From concepts on paper to the opening of Axiom Space, Collins Aerospace, and Intuitive Machines, the journey has been nothing short of extraordinary,” says Arturo Machuca, director of Ellington Airport and the Houston Spaceport, in a news release. “These anchor tenants, collectively holding about $5 billion in contracts with NASA and other notable aerospace companies, are not just shaping the future of space exploration but injecting vitality into Houston’s economy.” Continue reading.

Houston college lands $5M NASA grant to launch new aerospace research center

The five-year grant from NASA will go toward creating the NASA MIRO Inflatable Deployable Environments and Adaptive Space Systems Center at UH. Photo via UH.edu

The University of Houston was one of seven minority-serving institutions to receive a nearly $5 million grant this month to support aerospace research focused on extending human presence on the moon and Mars.

The $4,996,136 grant over five years is funded by the NASA Office of STEM Engagement Minority University Research and Education Project (MUREP) Institutional Research Opportunity (MIRO) program. It will go toward creating the NASA MIRO Inflatable Deployable Environments and Adaptive Space Systems (IDEAS2) Center at UH, according to a statement from the university.

“The vision of the IDEAS2 Center is to become a premier national innovation hub that propels NASA-centric, state-of-the-art research and promotes 21st-century aerospace education,” Karolos Grigoriadis, Moores Professor of Mechanical Engineering and director of aerospace engineering at UH, said in a statement. Continue reading.

View All Listings